PerryBoryeeShiehMDPhD

Neurology • Los Angeles, CA

Neuromuscular Medicine, Neurophysiology

Professor of Neurology and Pediatrics, UCLA School of Medicine

Join to view full profile

Dr. Shieh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shieh's full profile

Already have an account?

Office
300 UCLA Medical Plaza
Suite B200
Los Angeles, CA 90095
Phone+1 310-825-3264

Fax+1 310-825-3264

Summary

Dr. Perry Shieh is a neurologist at the University of California Los Angeles (UCLA). He received his medical degree from Johns Hopkins University School of Medicine and has been in practice 17 years. He specializes in neuromuscular medicine and neurophysiology and is experienced in neuromuscular medicine and clinical neurophysiology. He has more than 70 publications and over 500 citings.

Education & Training

Brigham and Women's Hospital/Children's Hospital/Harvard Medical SchoolFellowship, Clinical Neurophysiology, 2004 - 2005
Stanford Health Care-Sponsored Stanford UniversityResidency, Neurology, 2001 - 2004
Yale-New Haven Medical CenterInternship, Internal Medicine, 2000 - 2001
Johns Hopkins University School of MedicineClass of 2000

Certifications & Licensure

CA State Medical License 2002 - 2026
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Clinical Neurophysiology
American Board of Psychiatry and Neurology Neuromuscular Medicine

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies Start of enrollment: 2010 Feb 01
Completed
Phase 2, Phase 3
A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy Start of enrollment: 2012 May 01
Completed
Phase 2
Finding the Optimum Regimen for Duchenne Muscular Dystrophy Start of enrollment: 2013 Jan 01
Completed
Phase 3
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis Start of enrollment: 2014 May 01
Completed
Phase 2
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy Start of enrollment: 2014 Aug 19
Terminated
Phase 3
A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy Start of enrollment: 2014 Dec 01
Completed
Phase 1
RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR Start of enrollment: 2015 May 05
Completed
Phase 2
Study of Eteplirsen in DMD Patients Start of enrollment: 2014 Nov 17
Completed
Phase 3
An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort Start of enrollment: 2014 Dec 01
Completed
Phase 1
Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy Start of enrollment: 2015 Jun 30
Completed
Phase 2
A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA). Start of enrollment: 2015 Aug 19
Terminated
Phase 2
Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients Start of enrollment: 2015 Oct 08
Completed
Phase 1
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) Start of enrollment: 2016 Nov 01
Completed
Phase 3
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD) Start of enrollment: 2018 Feb 05
Completed
Phase 1
Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy Start of enrollment: 2017 Dec 14
Terminated
Phase 1
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD Start of enrollment: 2018 Mar 05
Active, not recruiting
Multi-Center Study of ManNAc for GNE Myopathy Start of enrollment: 2022 Apr 05
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Current insights in ultra-rare adenylosuccinate synthetase 1 myopathy - meeting report on the First Clinical and Scientific Conference. 3 June 2024, National Centre fo...
Emma Rybalka, Hyung Jun Park, Atchayaram Nalini, Dipti Baskar, Kiran Polavarapu
Orphanet Journal of Rare Diseases. 2024-11-26
3 citations
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.
Rabi Tawil, Kathryn R Wagner, Johanna I Hamel, Doris G Leung, Jeffrey M Statland
The Lancet. Neurology. 2024-05-01
6 citations
Recurrent de novovariant causes childhood-onset amyotrophic lateral sclerosis (ALS) by excess sphingolipid synthesis.
Safoora B Syeda, Museer A Lone, Payam Mohassel, Sandra Donkervoort, Pinki Munot
Journal of Neurology, Neurosurgery, and Psychiatry. 2024-01-11

Press Mentions

Muscular Dystrophy Gene Therapy Nears Approval, but Safety Concerns LingerMay 23rd, 2023
Astellas to Acquire Audentes for $3B, Seeing Gene Therapy as “Key Driver”December 3rd, 2019
CBS 2 Exclusive: Man’s Incurable, Deadly Disease Could Be Treated — if He Had $400,000 A YearMay 20th, 2017